Adiós a Melina Furman: "la mejor consejera del mundo, la curiosa extrema", en el recuerdo de Diego Golombek - clarin.com.ar/revista-n/adio… via Clarín

Seguimos intentando procesar la tristeza infinita que nos dejó la partida de Meli. Para honrar su vida, compartimos algunas de sus infinitas ideas. El recuerdo de lo que nos dejaste, nos da mucha motivación intrínseca para seguir aprendiendo durante toda la vida. Gracias Meli.

❓LC-CRT vs. SC-RT for Rectal Cancer Organ Preservation❓ MSKCC SOC: LC-CRT TNT, during COVID shifted to SC-RT Study demonstrated: 🟢🟰cCR rates (~ 40%) 🟢🟰 OS and DFS 🧐 ⬇️Regrowth ⬆️Organ Preservation w/ LC-CRT 🔥Suggests LC-CRT preferred for NOM German AIO-18 to clarify

📣📣📣The best way to start ESMO2024 for neuroendocrine community! Amazing session, brilliant speakers, vibrant discussions. Lovely friends and colleagues and more 🚨CMV-118 in progressive NET 🚨CABONEN in low G3 NEN 🚨NETTER-2 and new insights 🚨Carcinoid heart disease and NET

Time to move away from radiotherapy in operable GEA #ESMO24 TOPGEAR ➡️ no survival benefit when RT added to periop chemo TOPGEAR + ESOPEC : both great trials with a definitive answer = no more RT ✅Great drugs in development - let's focus on systemic Rx for cure ESMO - Eur. Oncology

#ESMO24: First-line #immunotherapy combination significantly improves OS in HER2+ metastatic #gastric or #GEJ adenocarcinoma regardless of PD-L1 status and could become new standard-of-care comparator in future #ClinicalTrials. #ESMODailyReporter 👉ow.ly/uLCv50TnqR2

TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: nej.md/4gg4gqv #ESMO24

#ESMO24 KEYNOTE-811: pembrolizumab + trastuzumab and chemotherapy for HER2+ metastatic G/GEJ adenocarcinoma: Final overall survival mFU: 50.2 mo mOS➡️20.0 vs 16.8 mo PD-L1 CPS ≥1➡️20.1 vs 15.7 mo Presented by Sara Lonardi

🚨#TOPGEAR ⚙️ results at #ESMO24 RCT: periop chemo w rads 🆚 no rads 👥 574 gastric/GEJ adenocarcinoma ⬆️ pCR with rads ❌ No difference in OS or PFS 🙅🏻‍♀️ That settles it then? 🤨 📝👇🏻

🗣️Insightful discussions on #NETs are unfolding at #ESMO2024 in Barcelona! We're excited to learn about the latest developments. Follow us to stay in the loop! x.com/FRANCES8818958…

#ESMO24 I ABS1148MO 🔥📊NETTER-2 update: 177Lu-DOTATATE + octreotide 30mg LAR shows PFS HR 0.212 (95% CI: 0.134-0.337) vs high-dose octreotide (0.276), ORR odds ratio 10.43 (95% CI: 3.98-27.29) vs 7.81. No new safety concerns. Is this a new standard of care? #MedEd

Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III CRC #ESMO24 🔎Phs II LEANOX trial 👉Neurotoxicity 42% vs 67% 👉Adjusted dosing = higher cumulative dose, no impact on OS & improves QoL 🧐strongly supports dose adjustments

New 1L SoC in metastatic #analcancer : Retifanlimab + CarboTax vs CarboTax: ✅ PFS: 9.3 vs 7.4 mo ✅ OS trend: 23 vs 29 mo ✅ ORR: 48% vs 36% Congrats Sheela Rao et al👏👏 Just missed participation of countries where #analcancer is frequent (Brazil, South Africa )

LEANOX trial: a way to decrease the neurotoxicity of oxaliplatin... you have to adapt the dose to Lean Body Mass. Congratulations to Eric Assenat for this academic positive study!! #ESMO24

#ESMO24 Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2 🔍One dose of ipilimumab and two doses of nivolumab prior to surgery, 64% had cT4 tumors. 3-year DFS➡️💯% Presented by Myriam Chalabi

Happening Now: Niche-2 3y DFS. 100% DFS, ctDNA- Congratulations Myriam Chalabi and team! Awesome #ESMO24 #CRC #MSI

🔥🔥🔥#ESMO2024 NICHE2: 3yDFS 💯 % 🎤drop + rapid ctDNA clearance NICHE 3 relatlimab+nivo: 68% pCR similar to NICHE2 but numerically ⬆️ gr 3-4AE IMHOTEP: pCR 53% with 1-2 doses pembro 👏🏽👏🏽👏🏽 Myriam Chalabi Dr. Peter de Gooyer Christelle de la Fouchardiere, MD Superb discussion by

Lower doses of everolimus similarly effective to standard dose in pts w #neuroendocrinetumors this set the basis for our EVENET trial (now open). NCT06472388 #ESMO2024 A.C.Camargo Cancer Center

Hot off the press, Alliance CABINET! Cabozantinib in previously treated (93% had SSA, 60% had PRRT, 72% had everolimus) advanced NETs. The primary endpoint, PFS, was significantly better in the cabo arm than placebo. Alliance for Clinical Trials in Oncology nejm.org/doi/full/10.10…

🚨 New #LowerGI cancer data from #ESMO24 🚨 Profs. Chiara Cremolini & Hans Prenen joined us at the congress to each share their insights on new rectal & colorectal cancer data from NICHE-2, NICHE-3 & IMHOTEP trials. 📺Watch their video update Supported by Bayer #Meded #CRC